Table 2.

Study Treatment

Treatment Characteristic	Treatment Strata
	Platinum Sensitive (n = 83)		Platinum Refractory (n = 106)
	Arm A: Ziv-Aflibercept + Topotecan (n = 42)	Arm B: Topotecan (n = 41)	Arm A: Ziv-Aflibercept + Topotecan (n = 55)	Arm B: Topotecan (n = 51)
No. of cycles administered
Median	2	2	2	2
Range	1-13	1-10	1-11*	1-6
Reason for discontinuation
Adverse events	8	1	10	5
Refusal unrelated to adverse events	3	4	5	3
Progression/relapse	24	33	35	39
Death	2	1	0	2
Other (not specified)	4	1	5	2
Major protocol deviations	1	2	3	3

^*Maximum No. of cycles of ziv-aflibercept was 9.